Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Sep;30(9):1841-1849.
doi: 10.3201/eid3009.231448.

Medical Costs of Nontuberculous Mycobacterial Pulmonary Disease, South Korea, 2015-2019

Medical Costs of Nontuberculous Mycobacterial Pulmonary Disease, South Korea, 2015-2019

Shihwan Chang et al. Emerg Infect Dis. 2024 Sep.

Abstract

Nontuberculous mycobacterial pulmonary disease (NTM-PD) prevalence is a rising public health concern. We assessed the long-term healthcare systems perspective of costs incurred by 147 NTM-PD patients at a tertiary hospital in South Korea. Median cumulative total medical cost in managing NTM-PD patients was US $5,044 (interquartile range US $3,586-$9,680) over 49.7 months (interquartile range 33.0-68.2 months) of follow-up. The major cost drivers were diagnostic testing and medication, accounting for 59.6% of total costs. Higher costs were associated with hospitalization for Mycobacterium abscessus infection and pulmonary comorbidities. Of the total medical care costs, 50.2% were patient co-payments resulting from limited national health insurance coverage. As South Korea faces significant problems of poverty during old age and increasing NTM-PD prevalence, the financial and socio-economic burden of NTM-PD may become a major public health concern that should be considered with regard to adequate strategies for NTM-PD patients.

Keywords: Nontuberculous mycobacteria; South Korea; bacteria; cost of illness; health expenditures; healthcare costs; pulmonary disease; tuberculosis and other mycobacteria.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Patient selection for study of medical costs of nontuberculous mycobacterial pulmonary disease, South Korea, 2015–2019. NTM, nontuberculous mycobacteria; PD, pulmonary disease.
Figure 2
Figure 2
Diagnostic and treatment timeline for study of medical costs of nontuberculous mycobacterial pulmonary disease, South Korea, 2015–2019. The index date was defined as the date of the first pulmonology visit in which the physician initially evaluated the patient for NTM-PD. NTM, nontuberculous mycobacteria; PD, pulmonary disease.
Figure 3
Figure 3
Cost proportion analysis by follow-up period, in study of medical costs of nontuberculous mycobacterial pulmonary disease, South Korea, 2015–2019. Cumulative cost was analyzed by each follow-up period. Numbers within bars represent the percentage of each cost category.

Similar articles

Cited by

References

    1. Jeon D. Infection source and epidemiology of nontuberculous mycobacterial lung disease. Tuberc Respir Dis (Seoul). 2019;82:94–101. 10.4046/trd.2018.0026 - DOI - PMC - PubMed
    1. Daley CL, Iaccarino JM, Lange C, Cambau E, Wallace RJ Jr, Andrejak C, et al. Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline. Clin Infect Dis. 2020;71:e1–36. 10.1093/cid/ciaa241 - DOI - PMC - PubMed
    1. Stout JE, Koh WJ, Yew WW. Update on pulmonary disease due to non-tuberculous mycobacteria. Int J Infect Dis. 2016;45:123–34. 10.1016/j.ijid.2016.03.006 - DOI - PubMed
    1. Griffith DE, Aksamit TR. Managing Mycobacterium avium complex lung disease with a little help from my friend. Chest. 2021;159:1372–81. 10.1016/j.chest.2020.10.031 - DOI - PubMed
    1. Adjemian J, Prevots DR, Gallagher J, Heap K, Gupta R, Griffith D. Lack of adherence to evidence-based treatment guidelines for nontuberculous mycobacterial lung disease. Ann Am Thorac Soc. 2014;11:9–16. 10.1513/AnnalsATS.201304-085OC - DOI - PMC - PubMed

Publication types